Clinical Trial Search

Primary: Time to Successful Radial Arterial Catheterization — 104; 104 seconds

Primary: Composite Local Skin Reaction (LSR) Score 3 Days After Treatment of Each Selected Treatment Area — 10.4; 9.7 units on a scale — p=0.13

Primary: Percentage Increase in Terminal Hair Counts From Pre-Treatment, Baseline for Active Test Subjects Over the Placebo Test Subjects. — 12.48; 63.67 percent change — p=<0.001

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Overall Response to CVT Chemotherapy. — 1; 5 participants

Primary: Percentage of Patients With an Increase in Macroscopic Conjunctival Hyperemia in Either Eye — 34.3; 39.1 Percentage of Patients

Primary: Overall Sensitivity and Specificity of Pefakit and Hemosil. — 83.3; 77; 81.5; 59.3 percentage of cases

Primary: Headache Relief — 47; 73 participants

Primary: Change From Period Baseline in FEV1 (L) AUC(0-24h) — 0.209; 0.165; 0.154; 0.121 Liters

Primary: AUX-I Cmax After Injection 1 — 12.6 ng/mL

Primary: Sensitivity and Specifity of Transient Elastography in Detection of Liver Cirrhosis — 0.83; 1.00; 1.00; 0.97 Probability

Primary: The Difference in the Arithmetic Mean of Core Body Temperature Measurements During the Perioperative Phase Between the Interventional Treatment Group and the Control…

Primary: Change From Baseline in Mean Oxygen Consumption (mL/kg/Min) at 6 Weeks — 30.5; 30.5; 31.3; 31.3 mL/kg/min — p=0.73

Primary: Progression-free Survival (PFS) — 7.5; 7.6; 9.2; 7.4 Months — p=0.89

Primary: 6 Month Progression-free Survival Rate (PFS) (Based on Combined Response Evaluation Criteria In Solid Tumours (RECIST) v1.1 +/- Gynecologic Cancer Intergroup (GCIG)…